GLP-1 'what I eat in a day' videos: separating real from reel

What did @alexisanneg actually say?

Honestly? Nothing we can fact-check. The transcript captured by this video is entirely song lyrics, not dietary advice. Lines like "I take your dreams and make them multiply" and "This rock on beef, I was grow" are garbled captures of background music, not the creator's spoken words about food, GLP-1 medications, or weight loss. There are zero audible health claims in this transcript to evaluate.

This is a common transcription failure with videos that use popular audio tracks. The actual content, presumably footage of meals eaten while on Zepbound (tirzepatide), was visual. The spoken or on-screen text, if any, did not get captured. We cannot attribute any specific dietary or medical claims to @alexisanneg based on what's here.

Does the science back this up?

There's nothing to back up or refute from the transcript itself. But since this video sits squarely in the Zepbound and PCOS space based on its hashtags, it's worth covering what the evidence actually says about eating patterns on GLP-1 receptor agonists, since that's almost certainly what the visual content showed.

Tirzepatide, the active ingredient in Zepbound, is a dual GIP and GLP-1 receptor agonist. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found participants lost up to 20.9% of body weight over 72 weeks at the highest dose. A significant part of that mechanism is appetite suppression and slowed gastric emptying, which naturally changes how much and what people can comfortably eat. So "what I eat in a day" content from Zepbound users does reflect a real, medication-driven shift in eating behavior, not just willpower.

For PCOS specifically, a 2023 review in Frontiers in Endocrinology noted that GLP-1 receptor agonists may improve insulin sensitivity and androgen levels in women with PCOS, though tirzepatide's specific data in this population is still limited.

What did they get wrong (or right)?

We cannot score the creator right or wrong here. The transcript is unusable. What we can say is that the video format itself, showing real meals eaten on a GLP-1 medication with PCOS context, is one of the more grounded genres of health content on TikTok. It's observational. It's personal. It doesn't usually involve dosing recommendations or disease cure claims.

That said, "what I eat in a day" content carries a quiet risk even when well-intentioned. Viewers may interpret another person's GLP-1 eating pattern as a template. Caloric intake on tirzepatide varies enormously by dose, individual tolerance, and how long someone has been on the medication. What works for one person at week 12 on 10mg may be inadequate protein intake for someone else. Nutritional needs don't disappear because appetite does. Researchers have flagged lean mass loss as a concern with rapid GLP-1-driven weight loss (Wilding et al., 2021, NEJM, on semaglutide), making protein prioritization genuinely important, not just a TikTok talking point.

What should you actually know?

If you're on Zepbound or considering it, the most important nutritional fact is this: GLP-1 medications suppress appetite aggressively, and that creates a real risk of eating too little protein. Studies suggest adults need at least 1.2 to 1.6 grams of protein per kilogram of body weight during active weight loss to preserve muscle mass (Phillips and Van Loon, 2011, Journal of Sports Sciences). Most people eating intuitively on GLP-1s fall short of that without intentional planning.

For people with PCOS, there's a reasonable case for GLP-1 therapy beyond weight loss. Insulin resistance drives many PCOS symptoms, and reducing it through weight loss and direct receptor activity may help. But tirzepatide is not approved specifically for PCOS, and any use in that context is off-label. A prescribing clinician should be involved in that decision, not a TikTok video.

Finally, Zepbound and compounded tirzepatide are not the same product. If you're being offered compounded tirzepatide, know that it has not undergone the same FDA approval process as the brand-name drug. This distinction matters clinically and legally.